Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma

@article{Ueda2010EvaluationOE,
  title={Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma},
  author={Shigeru Ueda and Ken Shirabe and Kazutoyo Morita and Kenji Umeda and Hiroto Kayashima and Hideaki Uchiyama and Yuji Soejima and Akinobu Taketomi and Yoshihiko Maehara},
  journal={Annals of Surgical Oncology},
  year={2010},
  volume={18},
  pages={1204-1211}
}
Excision repair cross-complementation group 1 (ERCC1) is one of the key enzymes in DNA repair. This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC). Eighty-seven HCC samples were analyzed by immunohistochemistry for ERCC1 and chemosensitivity was assessed by the succinate dehydrogenase inhibition (SDI) test for four anti-cancer agents, including CDDP. The ERCC1 expression was… CONTINUE READING